Abstract: Several gold(I) complexes with cysteine-containing dipeptides have been prepared starting from cystine by coupling different amino acids and using several orthogonal protections. The first step is the reaction of cystine, where the sulfur center is protected as disulfide, with Boc 2 O in order to protect the amino group, followed by coupling of an amino acid ester; finally the disulfide bridge is broken with mercaptoethanol to afford the dipeptide derivative. Further reaction with [AuCl(PPh 3 )] gives the gold-dipeptide-phosphine species. Starting from these formally gold(I) thiolate-dipeptide phosphine complexes with the general formula [Au(SR)(PR 3 )] different structural modifications, as change in the type of the amino protecting group, the type of phosphine, the number of gold(I) atoms per molecule, or the use of a nonproteinogenic conformationally-restricted amino acid ester, were introduced in order to evaluate their influence in the biological activity of the final complexes. The cytotoxic activity in vitro of these complexes has been evaluated against different tumour human cell lines (A549, MiaPaca2 and Jurkat). The complexes show an outstanding cytotoxic activity with IC 50 values in the very low micromolar range. Structure-Activity Relationships (SAR) observed from the complexes opens the possibility to the design of more potent and promising gold(I) anticancer agents.
Introduction
Metal-based drugs are an important class of compounds in medicinal chemistry employed clinically for the treatment of different diseases. 1 Cisplatin and the following generations of platinum based drugs are among the most widely used chemotherapeutic agents. 2 However their effectiveness is still restricted by several clinical problems, such as a limited spectrum of activity, development of resistance and undesired toxic side-effects. The use of different metal compounds with different biological properties and targets has emerged as an alternative strategy to overcome these limitations. Gold compounds have been employed since last century for the treatment of rheumatoid arthritis and in the last decades some gold(I) and gold(III) complexes with promising biological activities as anticancer, antimicrobial, fungicidal, anti-HIV, or in the treatment of asthma or parasitic diseases, among others, have been prepared. 3 In addition, the mechanistic studies showed that, in general DNA is not the main target and interactions with several enzimes, 4 and more specifically the seleno-enzime thioredoxine reductase, 5 proteasome, 6 kinases, 7 among others have been reported as a mode to finally lead to apoptosis through a mitochondrial pathway. Diverse approaches have been used to prepare gold(I) and gold(III) drugs. For gold(I) the synthesis has been focused on the use of auranofin analogues 8 or the coordination to gold of several ligands mainly phosphines, 9 and carbenes. 10 For gold(III), cyclometallated complexes or coordination to the metallic centre of bypiridine, dithiocarbamate or porphyrin ligands have been successfully employed in order to prepare new anticancer gold drugs.
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Surprisingly and in spite of the great number of reported gold complexes which show activity in the biological systems, the number of gold species with biomolecules such as amino acids and peptides is very scarce. Peptide research on drug design and drug discovery is one of the most promising fields in the development of new drugs. Peptide sequences are constituents of larger proteins, where they are responsible for molecular recognition and biological activities. 12 There are only a few reports of reactions of gold(I) and mainly gold(III) with amino acids such as cysteine and methionine. 13 Gold(I) peptides with the cysteine-modified neuropeptide encephalin 14 and by gold(I) azide cycloaddition reactions with alkynyl peptides have been reported by Metzler-Nolte and coworkers. 15 The latter type of compounds has shown to overcome cisplatin resistance in a p53-mutant cancer cell line. The crystal structure of a gold(I) complex with the human glutathione reductase 16 and also a gold protein with the AuPEt 3 fragment bonded to a histidine rest 17 have been reported, and could give interesting insights in the biological function of gold compounds. We have previously reported in the synthesis and functionalisation of gold(I)-phosphine-nicotinic acid thiolate with amino acids providing complexes with very good cytotoxic activity. 18 Additionally, gold(III) peptide derivatives with histidine residues, 19 and dithiocarbamate functionalised dipeptides have also been described. 20 In this context and with the aim of preparing more active and selective gold drugs, we propose the formation of gold(I) complexes with dipeptides. The introduction of peptides in the complexes might decrease the undesired toxic side-effects (they are biocompatible ligands) and they could serve as good carriers to deliver the gold atom to the biological target. 21 A major problem for cancer chemotherapeutics is crossing the cell membranes, and a strategy to overcome this is to make use of the peptide-based delivery systems, which can transport small peptides and peptide-like drugs to the cells. These peptide transporters over-express receptors in some types of tumours, these could be target by the gold-peptide compounds providing then with more internalization and subsequent selectivity. 20 Here we report on an efficient and general method to prepare dipeptides containing a cysteine moiety and different proteinogenic amino acids, using different orthogonal protections. The coordination of these dipeptides to a gold(I) phosphine fragment gives novel and stable gold-peptide bioconjugates, which cytototoxic activity has been studied. Several structural modifications of this peptide-gold-phosphine symptom have been performed in order to know which factor could improve their activity. Consequently, changes in the phosphine ligand, the amino protecting group, the number of coordinated AuPPh 3 + units, or other modifications, such as the introduction of a conformationally-restricted non-proteinogenic amino acid (Oic) in the peptide have been performed. Cytotoxic activity in vitro against different tumour cell lines has been analysed, showing outstanding cytotoxicity in all cases with IC 50 values in the very low micromolar range.
Results and Discussion

Synthesis and characterization
Gold(I) dipeptide phosphine complexes. In our aim of preparing gold complexes with cysteine-containing dipeptides we though in using as precursor the previously described complex Ac-Cys(AuPPh 3 )-OH, in which there is an acid moiety that could couple with other amino acid esters, in a similar manner as we have reported earlier for the gold-phosphine complexes with the nicotinic acid thiolate. 18a However, the preparation of the desired complexes was not possible by this route, probably because of solubility reasons. Then, a new synthetic strategy was selected, which consist on the use of commercially available cystine with the use of different orthogonal protecting groups for each functional unit (amino, carboxylic acid and thiol) of the dipeptide. 22 In the cystine the sulfur atom is already protected as disulfide, and then the first step consisted on the protection of the amino group, using the Boc (tert-butoxy carbonyl) protecting group according to previously described conditions (Scheme 1). The success of the reaction was easily confirmed by 1 H NMR, whose spectrum shows the appearance of the signals corresponding to the Boc group at  = 6.79 (carbamate proton) and 1.36 ppm (alkyl protons). The following step is the coupling of the amino acid ester through the free carboxylic acid of (Boc-Cys-OH) 2 through standard solution peptide chemistry (employing PyBOP as activating agent and DIPEA as base), and subsequent flash chromatography yielded 1a-6a derivatives in good yields. Six proteinogenic amino acid esters from glycine, alanine, valine, phenylalanine, methionine or proline were selected to prepare the dipeptide ligands. Each amino acid differs in the side chain group, what determines properties as lipophilicity, polarity, reactivity or steric hindrance, and could have influence in the exchange reactions that are supposed to give the final complexes with other biomolecules in the organism, affecting to the final activity, selectivity or biodistribution of the complex.
. Scheme 1. Synthesis of the gold(I) dipeptide complexes 1-6.
As common features, the 1 H and 13 C-NMR NMR spectra of compounds 1a-5a show, in addition to all the expected resonances for the molecule, the signals belonging to the new amide bond in the range  = 8. .40 ppm and  = 170.5-169.2 ppm, respectively. Compound 6a appears as a mixture of rotamers (ratio 1:0.2) as consequence as the conformationallyrestricted structure of proline, which possesses a five-membered ring (pyrrolidine) in its structure, giving a more complex spectrum. Selective reduction of the disulfides of 1a-6a employing a strong reducing thiol (-mercaptoethanol) 23 in soft basic media (DIPEA) afforded the desired dipeptide thiol ligands 1b-6b. Six different dipeptides containing cysteine groups have been prepared according to the synthetic route showed in Scheme 1: Boc-Cys-Gly-OMe (1b), Boc-Cys-Ala-OMe (2b), BocCys-Val-OMe (3b), Boc-Cys-Phe-OMe (4b), Boc-Cys-Met-OMe (5b) and Boc-Cys-Pro-OMe (6b). The 1 H-NMR spectra present the resonance for the thiol group as a doublet of doublets or as a multiplet in the range  = 1.46-1.90 ppm, while the resonances corresponding to C protons appear each one with a characteristic shape as a doublets of doublets of doublets (diastereotopic protons). The IR spectra also present the absorption bands corresponding to the thiol group in the range 2562-2580 cm -1 as weak bands. The dipeptides 1b-6b are valuable ligands that easily react with [AuCl(PPh 3 )] employing K 2 CO 3 as a base, to give the desired complexes 1-6 in high yields after chromatographic purification. Complexes 1-6, just as all the complexes reported in this work, were fully characterized by 1 H,
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C and 31 P NMR spectroscopy, IR spectroscopy and MS spectrometry. The 1 H NMR spectra show the resonances corresponding to the dipeptide and triphenylphosphine protons. The proton for the thiol group has desappeared, which agrees with coordination of the sulfur to gold affording the desired complexes. Remarkably, as a common feature, the resonances of the C protons (diastereotopic protons) are simplified and each one appears as a doublet of doublets at  = 3.60 and  = 3. 25 C HMBC experiments. The IR spectra present, among others, the absorptions for the amide, ester and aromatic unit and also the disappearance of the absorptions for the thiol group. The mass spectra (HRMS ESI+) presents for all the compounds the molecular peak [M+Na] + and [M+H] + . The different gold(I) complexes with the dipeptides are shown in Figure 1 . Structural modifications. The structure of complexes 1-6 described above, allows the introduction of several structural modifications with the purpose of obtaining information on how the changes in the structure affect the biological properties of the complexes, and thus can stablish a structure activity relationship (SAR), and can obtain compounds with better activity, selectivity and pharmaceutical profile. The selected structural modifications performed were the following: a) type of phosphine (7), b) type of amino protecting group (8), c) coupling of a non-proteinogenic conformationally restricted amino acid ester (9), and d) charge and number of gold atoms per molecule (10-11). All of these modifications could have influence in changing the polarity, electronic or steric properties of the complex, activity or selectivity and others as biodistribution or reactivity towards other biomolecules in the organism of the final complex. The different modifications carried out are summarized in Figure 2 . H} NMR spectra present a unique resonance corresponding to the phosphorus of the 2-diphenylphosphino pyridine ligand, the chemical shift is observed at 37.0 ppm, a value similar to that observed for 1. IR and MS data agree with the proposed structure. b) Preparation of the complex with different amino protecting group (8). Boc (tert-butoxycarbonyl) was employed as the amino protecting group in the preparation of the complexes 1-6. In this case, the Z (benzyloxycarbonyl) group was selected in order to evaluate how this change affects the biologic activity. Although in both cases the amino group is protected as a carbamate, the change introduced could affect to the polarity or exchange reactions with other biomolecules in the organism, important for the activity and selectivity of the drug. The [Au(Z-Cys-Gly-OMe)(PPh 3 )] complex 8 was prepared following a similar synthetic route to that used in the preparation of complexes 1-6 (Scheme 3).
Scheme 3. Synthesis of complex 8
Again, orthogonal protection of the different functional groups in the molecule was necessary. In the first place, starting from the disulphide 1a, cleavage of Boc amino protecting group was carried out employing standard conditions by reaction with 3M HCl/AcOEt solution. Introduction of the Z protecting group was successfully achieved by reaction with a convenient source as Z-Cl, employing DIPEA as a base and DMAP as catalyst. The intermediate 8b was obtained in moderate yield after chromatographic purification. Discussion of spectroscopic data ( 1 H and 13 C-NMR spectra) is similar to described previously for his analogue 1b with the exception of the signals belonging to the benzyl group instead of the tert-butyl as can be found in the experimental section. Disulfide reduction was carried out in the same way as described above. Again, the 1 H-NMR spectrum of dipeptide 8c shows, as the most remarkable features, the appearance of the signal of the thiol group at  = 1.70 ppm as a doublet of doublets and the diastereotopic C protons appears each one with the characteristic shape as a doublet of doublet of doublets. The IR spectrum clearly shows a band corresponding to the absorption of the SH group at 2579 cm -1 . The last step consisted in the deprotonation of the thiol and coordination of the corresponding thiolate to the gold(I) center as described above to give the desired complex 8 in pure form and high yield. Complex 8 is also analogous to 1 and consequently in the spectroscopic data the same features are observed: the 1 H-NMR spectrum shows the disappearance of the thiol proton and the C protons resonance appears downfield shifted and with a more simplified shape. In the 13 C-NMR spectrum the signal belonging to C is also shifted downfield, and in the IR spectrum the thiol band also disappears after the formation of the complex, which agrees with the proposed structure. c) Preparation of the complex with different coupled amino acid ester (9). The type of amino acid ester has influence in the ability of the carrier to deliver the gold(I) to its target. In fact, in a previous work we observed that functionalisation with proline usually gives better cytotoxic complexes compared with other amino acids.
18b In this case, we decided to couple to the cystine derivative the octahydroindole amino acid ester (Oic), a nonproteinogenic bicyclic proline analogue. 24 This amino acid has been employed in the design of peptides with interesting pharmaceutical profiles, mainly because conformationally restricted amino acids help to fix conformations and have influence in the interactions with receptors in the organism. Moreover, the dipeptides containing this moiety could present a higher resistance to hydrolysis by diverse enzymes. For all of these reasons, the preparation of a complex bearing this moiety is expected to improve the activity and selectivity. The synthetic route employed to prepare the complex 9 is shown in the Scheme 4.
Scheme 4. Synthesis of complex 7
As can be observed, this synthetic route is essentially the same as described previously for the preparation of the dipeptide complexes 1-6 and will not be further discussed here. In this case, the coupling of another amino ester type was carried out. Similarly to complex 6 bearing the proline moiety, complex 9 appears as a mixture of rotamers in the NMR spectra. This complex possesses a high number of protons and carbon atoms, many of them showing similar chemical shifts. Nevertheless, all the signals could be correctly assigned by the realization of 2D-NMR experiments ( 
d) Preparation of the complexes with more number of gold atoms per molecule (10 and 11).
Diverse studies indicate that in gold(I) complexes with thiolates and phosphines as ligands, the cytotoxicity is due mainly to the metallic centre, whereas the phosphine ligand allow the gold(I) atom to cross the cellmembranes and the thiolate takes part in exchange ligand reactions with other biomolecules. Keeping in mind this, it is logical to think that adding more gold(I) atoms per molecule the cytotoxicity of the complex will increase, as we observed previously.
18b Moreover, nowadays there is a strong interest in the synthesis of lipophilic and cationic compounds which seem to be able to cross cell-membranes and selectively accumulate in mitochondria, 25 just where it seems that gold(I) complexes exert their therapheutic effect, by inhibiting diverse enzymes as for example Thioredoxin Reductase (TrX). Moreover, further coordination of gold(I) atoms to sulfur could have a strong influence in the transference reactions of the metal to other biomolecules, determining its transport, biodistribution or enzyme-inhibition ability. For all of these reasons, we carried out the synthesis of the dinuclear (10) and trinuclear (11) cationic complexes derived from the mononuclear complex 1 by reaction with the high electrophilic complex [Au(OTf)(PPh 3 )] generated in situ (Scheme 5).
Scheme 5. Synthesis of the dinuclear (10) and trinuclear (11) complexes derived from
Remarkably, the 1 H NMR spectrum of complex 11 appears as a mixture of rotamers in contrast with complexes 1 and 10, probably due to more steric hindrance. In all the cases we observed the expected resonances for the protons belonging to the dipeptide and triphenylphosphine. In the 1 H NMR spectra of complexes 10 and 11, the carbamate and amide protons, and all the protons belonging to the dipeptide appear more downfield shifted than observed for complex 1. Integration of aromatic protons corresponding to triphenylphosphine ligands also confirms the coordination of additional gold(I) triphenylphosphine moieties. The 19 F-NMR spectra show a single signal at  = -77,8 ppm that belongs to the triflate counter anion in both cases. However, the most notable feature is the chemical shift for the phosphorus atoms in the 31 P NMR NMR spectra, that appears at  = 33.2 ppm (dinuclear complex) and  = 32.3 ppm (trinuclear complex), that are strongly upfield shifted (4 and 5 ppm, respectively) compared with 1. The mass spectra (ESI+) presents the molecular peak [M] + .
Cytotoxic activity. The cytototoxic of complexes 1-11 was tested against three different human tumour cell lines: Jurkat (Tcell leukaemia), MiaPaca2 (pancreatic carcinoma) and A549 (lung carcinoma), compared to the results with cisplatin. Compounds 1-11 are not soluble in water, but they are soluble in DMSO and in the DMSO/water mixtures used in the tests, which contain a small amount of DMSO. We did not observe any precipitation of the complexes or metallic gold while performing the tests. The Jurkat and MiaPaca2 cell lines were the most sensitive to our compounds, whereas A549 showed more resistance to the complexes. The gold(I) dipeptide complexes (1-6) displayed very good cytotoxicity in all the tumour cell lines. The type of the proteinogenic amino ester coupled to cysteine has some influence in the cytotoxicity of the final complex: the complexes which incorporate glycine or proline in their structure showed the best IC 50 values. The change of the type of phosphine ligand coordinated to gold(I) (complex 7), the amino protecting group (complex 8) or the amino acid ester coupled to cysteine (complex 9) led to more potent complexes in the MiaPaca2 tumour cell line, although in the A549 resulted in a decrease of the cytotoxicity of the complex in comparison with the related complex 1. The coordination of an additional [AuPPh 3 ] + fragment (complex 10) to 1 has a strong influence in the cytotoxicity, mainly in the MiaPaca2 and Jurkat tumour cell lines. In particular, complex 10 was the most potent of all the series. Surprisingly, coordination of two additional [AuPPh 3 ] + fragments (complex 11) to 1 did not improve the potency of the complex. Then, the use of a dipeptide containing glycine or proline, or the coordination of two gold(I) centres to the sulfur atom, giving a cationic complex, yielded the most potent cytotoxic complexes.
Comparison of the activity of this family of gold-peptide derivatives with the anticancer drug cisplatin, shows that these complexes displayed much more in vitro cytotoxic activity. In relation with other gold(I)-peptide species our complexes have much lower IC 50 values, although comparison with the same cell lines is not possible. The activity is also higher than in the gold(I)-nicotinic acid thiolate functionalised with amino acids previously described by us.
14b Nevertheless the very low values obtained in these complexes in resistant cell lines as A549 and MiaPaca2 measured after 24 h represent outstanding values, which made them as very promising metallo-drugs candidates in order to continue their evaluation and mechanism studies .
Conclusions
A series of gold(I) complexes with cysteine-containing dipeptides have been prepared starting from cystine by coupling different amino acids, and using several orthogonal protections. In these molecules the gold centre is coordinated directly to the dipeptide, to the sulfur of the cysteine as thiolate. These novel derivatives with biologically relevant molecules could deliver the gold centre selectively to the tumour cells because they can act as peptidomimetics and target peptide delivery systems, which have over-expressed receptors in tumour cells. In this formally gold(I) thiolate-dipeptide phosphine complexes with the general formula [Au(SR)(PR 3 )] different structural modifications as change in the type of the amino protecting group, the type of phosphine, the number of AuPPh 3 + fragment coordinated to the sulfur centre, or the use of non-proteinogenic conformationally-restricted amino acid ester in the peptide, were introduced in order to evaluate their influence in the biological activity of the final complexes. The cytotoxic activity in vitro of these complexes has been evaluated against different tumour human cell lines (A549, MiaPaca2 and Jurkat). The complexes show excellent cytotoxic activity with IC 50 values in the very low micromolar range, as low as 0.1 M. The structural changes performed in the parent compound have led to the synthesis of the most effective compound in all the cell lines, which is the complex with two AuPPh 3 + fragments coordinated to the BocCys-Gly-OMe peptide.
Experimental Section
Experimental Details. Instrumentation. C, H, and N analysis were carried out with a PERKIN-ELMER 2400 microanalyzer. Mass spectra were recorded on a BRUKER ESQUIRE 3000 PLUS, with the 
Synthesis of compounds
General Procedure for coupling amino acid esters. Synthesis of compounds 1a-6a and 9a (Procedure A). To a solution of (Boc-Cys-OH) 2 (1 mmol) in anhydrous DMF (5 mL) was added the corresponding amino ester hydrochloride (2.4 mmol), PyBOP (2.2 mmol) and DIPEA (6.6 mmol). The mixture was stirred for 48 h under argon atmosphere at room temperature. Then, the resultant clear solution was diluted with AcOEt (100 ml) and washed with water (5 x 60 ml). The organic phase was dried over anhydrous MgSO 4 , filtered off and evaporated to dryness. The crude of the reaction was purified by column chromatography on silica gel using as eluent a mixture of ethyl acetate/hexane (1:1).
General Procedure for reducing disulfides to thiols. Synthesis of compounds 1b-6b, 8c and 9b (Procedure B). To a solution of the corresponding disulfide (Boc-Cys-aa-OMe) 2 (1 mmol) in dry CH 2 Cl 2 (50 ml), -mercaptoethanol (4 mmol) and DIPEA (4 mmol) were added. The mixture was stirred for 48 h under argon atmosphere at room temperature. Then, the solvent was evaporated under reduced pressure and the crude of reaction redissolved in AcOEt (100 ml) and washed with an aqueous saturated solution of KHSO 4 (3 x 40 ml) and a saturated aqueous solution of NaCl (3 x 40 ml). The organic phase was dried over anhydrous MgSO 4 , filtered off and evaporated to dryness. The crude of the reaction was purified by column chromatography on silica gel using as eluent a mixture of acetone/hexane (1:1).
General Procedure for the Synthesis of gold(I) dipeptide complexes 1-9 (Procedure C). To a solution of the corresponding dipeptide derivative Boc-Cys-aa-OMe (1 mmol) in acetone (10 ml) an excess of K 2 CO 3 (2 mmol) was added. The mixture was stirred for 5 min. Then, [AuCl(PPh 3 )] or [AuCl(PPh 2 Py)] (1 mmol) in acetone (10 ml) was added and the reaction mixture was stirred at room temperature for 24 h. After this time, the reaction mixture was filtered over celite and the clear solution evaporated under reduced pressure. Complexes 1-9 were purified by column chromatography of silica gel using as eluent a mixture of AcOEt/hexane (1:1).
(Boc-Cys-OH) 2 : To a 10% (w/w) K 2 CO 3 in water (70 ml) solution cystine (4.47 g, 18.6 mmol) was added. Then, a solution of Boc 2 O (10.2 g, 46.7 mmol) in THF (60 ml) was added. The mixture was stirred for 24 h under reflux (80º C), and after, diluted with water (120 ml). Carefully acidification by adding dropwise an aqueous saturated solution of KHSO 4 was carried out to a soft acidic media (pH = 3-4). The white precipitate observed was extracted with CHCl 3 (3x50 ml). The organic phases were collected, dried over anhydrous MgSO 4 , filtered off and evaporated, affording a white solid (7.78 g, 17. 7 mmol, yield = 95.0 %) which was employed without further purification. (Boc-Cys-Gly-OMe) 2 (1a): The reaction of (Boc-Cys-OH) 2 (1.32 g, 3 mmol), HCl·H-Gly-OMe (0.904 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the Procedure A, afforded 1a (1.517 g, 2.6 mmol) as a white solid (Yield = 86.8 %). (Boc-Cys-Phe-OMe) 2 (4a): The reaction of (Boc-Cys-OH) 2 (1.32 g, 3 mmol), HCl·H-Phe-OMe (1.553 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) (Boc-Cys-Pro-OMe) 2 (6a): The reaction of (Boc-Cys-OH) 2 (1.32 g, 3 mmol), HCl·H-Pro-OMe (1.438 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the Procedure A, afforded 6a (1.405 g, 2.1 mmol) as a white solid (Yield = 70.7 %). 
Boc-Cys-Gly-OMe (1b):
The reaction of 1a (0.234 g, 0.5 mmol), -mercaptoethanol (0.140 ml, 2 mmol) and DIPEA (0.34 ml, 2 mmol) following the Procedure B, afforded 1b (0.218 g, 0.75 mmol) as a white solid (Yield = 74.6 %). = 14.9, C1), 136.6 (d, CH, J = 11.0, C3), 134.6 (d, CH, J = 13.7, C7), 131.7 (d, CH, J = 32.8, C4), 131.6 (d, CH, J = 2.4, C9), 129.7 (C, C6), 129.5 (d, CH, J = 11.5, C8), 125.1 (d, CH, J = 2.3, C2) , 79.8 (C, C Boc ), 58.0 (C ,Cys H), 52.1 (OCH 3 ), 41.2 (C ,Gly H 2 ), 30.8 (C ,Cys H 2 ) and 28.3 (C Boc H 3 ). (HCl·H-Cys-Gly-OMe) 2 (8a): To a 3 N HCl/AcOEt solution (30 ml) 1a (1.025 g, 1.76 mmol) was added. The mixture was stirred for 24 h at room temperature. Then, the white precipitate was filtered off and dried, affording 8a (0.689 g, 1.51 mmol) as a white solid (Yield = 86.0%). This reaction can also be carried out employing TFA/CH 2 Cl 2 (1:1 v/v). (Z-Cys-Gly-OMe) 2 (8b): To a solution of 8a (1.366 g, 3 mmol) in CH 2 Cl 2 (12 ml) were added DIPEA (2.36 ml, 13.8 mmol), DMAP (cat.) and benzyl chloroformate (1.11 ml, 7.8 mmol) dropwise and at 0º C. Then, the mixture was stirred at room temperature overnight. The reaction was following by TLC until the reaction was completed and the solvent evaporated under reduced pressure. The crude was redissolved in AcOEt (50 ml) and washed with water (3 x 50 ml). The organic phases were collected and dried over anhydrous MgSO 4 , filtered off and evaporated to dryness. The crude of the reaction was purified by column chromatography on silicagel using as eluyent a mixture of AcOEt/hexane (8:2) to give 8b (0.787 g, 1.21 mmol) as a white solid (Yield = 40.4 %). (Boc-Cys-Oic-OMe) 2 (9a): The reaction of (Boc-Cys-OH) 2 (0.220 g, 0.5 mmol), HCl·H-Oic-OMe (0.241 g, 1.1 mmol), PyBOP (0.572 g, 1.1 mmol) and DIPEA (0.548 ml, 3.2 mmol) in anhydrous DMF (15 ml) 28.0, 25.6, 23.7 and 19.9 [Boc-Cys(AuPPh 3 ) 2 -Gly-OMe]OTf (10): To a solution of the complex 1 (0.072 g, 0.1 mmol) in CH 2 Cl 2 (5 ml) was added [Au(OTf)(PPh 3 )] (0.061 g, 0.1 mmol) freshly prepared. The mixture was stirred for 2 h at room temperature. Then, the yellow solution resultant was filtered on Celite. The solution was concentrated to ca. 5 ml and addition of hexane (20 ml) afforded 10 as an orange solid (0.122 g, 0,09 mmol), (yield = 90.0 %). Cell culture: Jurkat (leukaemia) and MiaPaca2 (pancreatic carcinoma) cell lines were maintained in RPMI 1640, while A549 (lung carcinoma) were grown in DMEM (Dulbecco´s Modified Eagle´s Medium). Both media were supplemented with 5% fetal bovine serum (FBS), 200 U/ml penicillin, 100 g/ml streptomycin and 2 mM L-glutamine. Medium for A549 cells was also supplemented with 2.2 g/l Na 2 CO 3 , 100 g/ml piruvate and 5 ml non-essential amino acids (Invitrogen). Cultures were maintained in a humidified atmosphere of 95% air/5% CO 2 at 37 ºC. Adherent cells were allowed to attach for 24 h prior to addition of compounds.
Cytotoxicity assay by MTT:
The MTT assay was used to determine cell viability as an indicator for cells sensitivity to the complexes. Exponentially growing cells were seeded at a density of approximately 1x105 cells/ml for the adherent cell lines (A549, MiaPaca2) or 5x104 cells/ml (Jurkat), in a 96-well flat-bottomed microplate and 24 h later they were incubated for 24 h with the compounds. The complexes were dissolved in DMSO and tested in concentrations ranging from 0.1 to 25 M and in quadruplicate. Cells were incubated with our compounds for 24 h at 37 ºC. 10 l of MTT (5 mg/ml) was added and plates were incubated for 1-3 h at 37 ºC. Finally, 100 µl/well i PrOH (0.05 M HCl) was added. The optical density was measured at 490 nm using a 96-well multiscanner autoreader (ELISA). The IC50 was calculated by non-linear regression analysis using Origin software (Origin Software, Electronic Arts, Redwood City, California, USA).
